Medscape

Arterial Stiffness Changes Linked to Development of Dementia in SPRINT Post Hoc Analysis

Pulse wave velocity, calculated from age and blood pressure changes, was associated with significant dementia risk in a post ...
Healio

Tirzepatide bests dulaglutide for lowering cardiorenal risk

In patients with type 2 diabetes and established CVD, tirzepatide conferred lower risk for cardiorenal adverse events compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT ...
Nasdaq

Amicus Therapeutics Publishes Positive Post-Hoc Analysis of Cipaglucosidase Alfa-Atga + Miglustat in Late-Onset Pompe Disease

Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
The American Journal of Managed Care

Post Hoc Analysis Findings Offer Guidance for Anemia Management in Myelofibrosis: Pankit Vachhani, MD

A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
EurekAlert!

New post-hoc analysis shows patients whose clinicians had access to GeneSight results for depression treatment are more likely to feel better sooner

SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
The American Journal of Managed Care

Oral Semaglutide Improves Cardiovascular Risk Factors in Type 2 Diabetes

Durability through 156 weeks favored semaglutide for HbA1c (−0.47%), weight (−3.26%), systolic BP (−1.83 mm Hg), and pulse ...
Nasdaq

CalciMedica Presents New Data From Post Hoc Analysis Of Phase 2 CARDEA Study Of Auxora

(RTTNews) - CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, Tuesday said it presented new data based on a post-hoc analysis from the previously completed Phase 2 CARDEA study of ...
Business Wire

Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...